Work

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Year: 2020

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(20)31105-9

Authors: I. Odintsov, E. Gladstone, W.J. Sisso, L. Delasos, A.J.W. Lui, E.M. Sisso, M. Vojnic, I. Khodos, M.S. Mattar, E. de Stanchina, D. Plessinger, S.M. Leland, M. Ladanyi, R. Somwar

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097674083

FWCI:

Cites:

Cited by:

Related to: 10